ES2192194T3 - Tratamiento medico que usa hormonas tiroideas. - Google Patents

Tratamiento medico que usa hormonas tiroideas.

Info

Publication number
ES2192194T3
ES2192194T3 ES94921305T ES94921305T ES2192194T3 ES 2192194 T3 ES2192194 T3 ES 2192194T3 ES 94921305 T ES94921305 T ES 94921305T ES 94921305 T ES94921305 T ES 94921305T ES 2192194 T3 ES2192194 T3 ES 2192194T3
Authority
ES
Spain
Prior art keywords
treatment
medical treatment
thyroid hormones
thyroid hormone
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94921305T
Other languages
English (en)
Inventor
Gilbert Mayor
Alecy Louis D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
Abbott GmbH and Co KG
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG, University of Michigan System, University of Michigan Ann Arbor filed Critical Abbott GmbH and Co KG
Application granted granted Critical
Publication of ES2192194T3 publication Critical patent/ES2192194T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA ISQUEMIA DEL SISTEMA NERVIOSO CENTRAL SE PREVIENE O MINIMIZA EN PACIENTES QUE HAYAN SUFRIDO UN PROCESO AGUDO ADMINISTRANDOLES UNA CANTIDAD PREVENTIVA DE HORMONA TIROIDEA TAL COMO LEVOTIROXINA, LIOTIRONINA, L-3,3`,5`-TRIYODOTIRONINA O L-3,5 DIYODOTIRONINA, PREFERIBLEMENTE EN FORMA DE SUS SALES DE SODIO. SE PUEDE OFRECER UNA DOSIS INICIAL EN FORMA DE PILDORA MAYOR DE LO NORMAL DE HORMONA TIROIDEA ANTES DE LA INICIACION DE LA ADMINISTRACION CONTINUA. EL TRATAMIENTO ESTA PARTICULARMENTE INDICADO PARA EL TRATAMIENTO DE LA ISQUEMIA CEREBRAL QUE SIGUE AL PARO CARDIACO.
ES94921305T 1993-06-22 1994-06-22 Tratamiento medico que usa hormonas tiroideas. Expired - Lifetime ES2192194T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7980593A 1993-06-22 1993-06-22

Publications (1)

Publication Number Publication Date
ES2192194T3 true ES2192194T3 (es) 2003-10-01

Family

ID=22152935

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94921305T Expired - Lifetime ES2192194T3 (es) 1993-06-22 1994-06-22 Tratamiento medico que usa hormonas tiroideas.

Country Status (11)

Country Link
US (1) US5571840A (es)
EP (1) EP0751769B1 (es)
JP (1) JPH09503485A (es)
KR (1) KR100348117B1 (es)
AT (1) ATE230986T1 (es)
AU (1) AU680669B2 (es)
CA (1) CA2165822A1 (es)
DE (1) DE69432027T2 (es)
DK (1) DK0751769T3 (es)
ES (1) ES2192194T3 (es)
WO (1) WO1995000135A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401891D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
EP1156940A4 (en) 1999-02-10 2006-02-08 Erik Zapletal BALANCED SUSPENSION SYSTEM
US6500834B1 (en) 1999-04-27 2002-12-31 Board Of Regents, The University Of Texas System Composition and method for treatment of cerebral ischemia
EP1223931B1 (en) * 1999-10-29 2005-12-14 Orion Corporation Use of a imidazole derivative for the treatment or prevention of hypotension and shock
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
CA2429196A1 (en) * 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US20020193440A1 (en) * 2001-02-20 2002-12-19 Ritter Steven C. Liothyronine sodium and levothyroxine sodium combination
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US20040156893A1 (en) * 2003-02-11 2004-08-12 Irwin Klein Method for treating hypothyroidism
ITRM20030363A1 (it) * 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
CA2539288C (en) * 2003-09-15 2015-05-12 Shaker A. Mousa Thyroid hormone analogs and methods of use
US8071134B2 (en) 2003-09-15 2011-12-06 Ordway Research Institute, Inc. Thyroid hormone analogs and methods of use
US9198887B2 (en) 2003-09-15 2015-12-01 Nanopharmaceuticals Llc Thyroid hormone analogs and methods of use
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
CN101102758B (zh) * 2004-09-15 2011-11-16 奥德威研究院 促进血管新生的甲状腺激素类似物
US20060128797A1 (en) * 2004-12-15 2006-06-15 Yanming Wang Method and composition for resuscitation
AU2006230557A1 (en) * 2005-03-31 2006-10-05 King Pharmaceuticals Research & Development, Inc. Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
US9220788B2 (en) 2009-06-17 2015-12-29 Nanopharmaceuticals Llc Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US10130686B2 (en) 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
US9498536B2 (en) 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
WO2007035612A2 (en) 2005-09-16 2007-03-29 Ordway Research Institute, Inc. Polyphenol conjugates as rgd-binding compounds and methods of use
EP2120913B1 (en) 2006-12-22 2015-01-21 NanoPharmaceuticals LLC Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
US9180107B2 (en) 2009-03-31 2015-11-10 Nanopharmaceuticals Llc Combination treatment of cancer with cetuximab and tetrac
SG175979A1 (en) * 2009-05-15 2011-12-29 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
US8802240B2 (en) 2011-01-06 2014-08-12 Nanopharmaceuticals Llc Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
WO2013090278A2 (en) 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US10060934B2 (en) 2013-11-18 2018-08-28 Nanopharmaceuticals Llc Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof
KR101848231B1 (ko) * 2015-06-29 2018-05-29 한양대학교 산학협력단 트리요오드티로닌, 티록신 또는 이의 염을 포함하는 뇌신경계 질환의 예방, 개선 또는 치료용 조성물
US10201616B2 (en) 2016-06-07 2019-02-12 Nanopharmaceuticals, Llc Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonists
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EP4732889A2 (en) 2017-06-07 2026-04-29 Supira Medical, Inc. Intravascular fluid movement devices, systems, and methods of use
US11511103B2 (en) 2017-11-13 2022-11-29 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
JP7410034B2 (ja) 2018-02-01 2024-01-09 シファメド・ホールディングス・エルエルシー 血管内血液ポンプならびに使用および製造の方法
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2020028537A1 (en) 2018-07-31 2020-02-06 Shifamed Holdings, Llc Intravascaular blood pumps and methods of use
WO2020073047A1 (en) 2018-10-05 2020-04-09 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
SI3908272T1 (sl) * 2019-01-09 2023-07-31 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. L-trijodotironin (t3) za uporabo pri omejevanju mikrovaskularne obstrukcije
WO2021011473A1 (en) 2019-07-12 2021-01-21 Shifamed Holdings, Llc Intravascular blood pumps and methods of manufacture and use
US11654275B2 (en) 2019-07-22 2023-05-23 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
EP4010046A4 (en) 2019-08-07 2023-08-30 Calomeni, Michael Catheter blood pumps and collapsible pump housings
EP4034221B1 (en) 2019-09-25 2024-11-13 Shifamed Holdings, LLC Catheter blood pumps and collapsible pump housings
WO2021062260A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible blood conduits
US12599758B2 (en) 2019-12-19 2026-04-14 Shifamed Holdings, Llc Intravascular blood pumps, motors, and fluid control
GR1010068B (el) * 2020-04-21 2021-09-01 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE" Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237435B (it) * 1989-12-14 1993-06-04 Farmaco attivo nel ripristino della plasticita' neuronale.
US5158978A (en) * 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
EP0466909B1 (en) * 1990-02-05 1995-06-28 British Technology Group (Usa) Incorporated Thyroid hormone for cardiac treatment

Also Published As

Publication number Publication date
JPH09503485A (ja) 1997-04-08
US5571840A (en) 1996-11-05
DE69432027T2 (de) 2003-10-09
KR100348117B1 (ko) 2002-12-02
AU680669B2 (en) 1997-08-07
AU7208094A (en) 1995-01-17
EP0751769A1 (en) 1997-01-08
WO1995000135A1 (en) 1995-01-05
EP0751769B1 (en) 2003-01-15
CA2165822A1 (en) 1995-01-05
DK0751769T3 (da) 2003-04-07
DE69432027D1 (de) 2003-02-20
ATE230986T1 (de) 2003-02-15
EP0751769A4 (en) 1998-05-27

Similar Documents

Publication Publication Date Title
ES2192194T3 (es) Tratamiento medico que usa hormonas tiroideas.
ES2156124T3 (es) Formulaciones que contienen acido hialuronico.
ES2153338T1 (es) Dosificacion mejorada de dosis multiples de medicamentos.
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
DK0586621T3 (da) Linsidomin til behandling af erektile dysfunktioner
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
MX9303969A (es) Uso de fosfonatos y farmacos antiinflamatorios no esteroidales para el tratamiento de artritis.
ES2082288T3 (es) Composiciones terapeuticas para administracion intranasal de ketorolaco.
BR0115392A (pt) Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
EP1064000A4 (en) VITAMIN D AND ITS ANALOGS FOR THE TREATMENT OF TUMORS AND OTHER HYPERPROLIFERATION DISORDERS
ES2098496T3 (es) Forma medicamentosa aplicable por via peroral para el tratamiento de estados de insuficiencia de dopamina en el sistema nervioso central.
AR004108A1 (es) Uso del 4-(4-fluorobencilamino)-2-amino-1-etoxicarbonilaminobenceno y sus sales farmaceuticamente aceptables para la preparacion de un medicamento destinado a la profilaxis y el tratamiento de las consecuencias de la insuficiencia aguda y crónica de la irrigacion sanguinea cerebral y el tratamiento de las enfermedades neurodegenrativas
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
ATE121627T1 (de) Verminderung oder verhütung der von arzneimitteln verursachten hautreizung.
ES2168241T1 (es) Preparacion farmaceutica que contiene tolperisona para administrar por via oral.
MX9305472A (es) Dispositivo distribuidor de medicamento.
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
CO5540323A2 (es) Administracion oral de hormona paratiroides y calcitonina
SMARR et al. Experiences with Marsilid with report of one death
ES2184880T3 (es) Asociacion hormonal estrogeno-progestageno, su procedimiento de preparacion y su utilizacion en medicamentos.
Mckinney Jr et al. Depression with the use of alpha-methyldopa
AR003979A1 (es) Administracion transdermica de vorozol.
ES2139013T3 (es) Compuestos de fosfonato que contienen nitrogeno cuaternario para tratar el metabolismo anormal del calcio y fosfato.
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol